SCHEMBL651145

SCHEMBL651145

CN1CCC(Oc2ccc(/N=C3/NC(=O)/C(=C/c4cnc(NC(=O)C5CC5)s4)S3)c(Cl)c2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RNASEL Q05823 1/20 0.40
MKNK1 Q9BUB5 1/20 0.38
HPGD P15428 2/20 0.37
ABL1 P00519 2/20 0.37
HCAR2 Q8TDS4 1/20 0.37
HCAR1 Q9BXC0 1/20 0.37
CCR1 P32246 1/20 0.36
HRH1 P35367 1/20 0.36
CCR3 P51677 1/20 0.36
HSD11B1 P28845 1/20 0.36
DYRK3 O43781 1/20 0.36
GPR119 Q8TDV5 3/20 0.35
GSK3B P49841 4/20 0.35
WEE1 P30291 1/20 0.35
TUBB4A P04350 1/20 0.35
TUBB P07437 1/20 0.35
TUBA3C P0DPH7 1/20 0.35
TUBA1B P68363 1/20 0.35
TUBA4A P68366 1/20 0.35
TUBB4B P68371 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10176480 0.93 MAPT (0.41) RNASELMKNK1HPGDABL1GPR119
SCHEMBL10176526 0.90 KDR (0.39) MKNK1ABL1DYRK3GPR119GSK3B
SCHEMBL10176507 0.89 MAPT (0.40) RNASELMKNK1HPGDABL1GPR119
SCHEMBL650007 0.88 MKNK1 (0.43) RNASELMKNK1HSD11B1DYRK3GSK3B
SCHEMBL699754 0.87 KDR (0.38) MKNK1ABL1DYRK3GPR119GSK3B
SCHEMBL653891 0.84 MAPT (0.41) RNASELHPGDABL1GPR119
SCHEMBL653892 0.84 MAPT (0.41) RNASELHPGDABL1GPR119
SCHEMBL649652 0.84 RNASEL (0.40) RNASELHPGDABL1HSD11B1DYRK3
SCHEMBL697898 0.84 MAPT (0.43) MKNK1HPGDABL1GSK3BWNT1
SCHEMBL650931 0.83 MKNK1 (0.42) RNASELMKNK1HPGDABL1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
WO-2010122979-A1 THIAZOLIDINONE DERIVATIVE SBIバイオテック株式会社 (JP) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 RNASEL 4113/4885MKNK1 275/4885HPGD 3970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.